Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jun 13;16(9):1898–1908. doi: 10.1158/1535-7163.MCT-16-0899

Figure 6. Conceptual model describing a role for IL6R blocking antibodies in enhancing the sensitivity of PDAC to chemotherapy.

Figure 6

STAT3 signaling in malignant and non-malignant cells in the tumor microenvironment of PDAC is associated with chemoresistance. Treatment with anti-IL6R blocking antibodies disrupts IL-6/STAT3 signaling in both malignant and non-malignant cells which suppresses tumor proliferation and enhances the sensitivity of PDAC to chemotherapy-induced apoptosis.